Leadership Overview
Exelixis has 4 executives leading key functions including financial strategy, operational coordination, clinical development, and legal compliance.
Focused on advancing oncology treatments, Exelixis delivers innovative medicines for difficult-to-treat cancers while maintaining a robust pipeline of tyrosine kinase inhibitors to improve patient outcomes across global markets.
Focused on advancing oncology treatments, Exelixis delivers innovative medicines for difficult-to-treat cancers while maintaining a robust pipeline of tyrosine kinase inhibitors to improve patient outcomes across global markets.
Leadership Roles at Exelixis
Christopher Senner - Executive Vice President & Chief Financial Officer
Christopher Senner, the Executive Vice President & Chief Financial Officer at Exelixis, directs all fiscal operations and capital allocation strategies. Overseeing the financial health of the organization, the Executive Vice President & Chief Financial Officer ensures the company maintains sufficient liquidity to fund ongoing research into cabozantinib-based therapies. This leadership role involves managing investor relations and providing transparent reporting on the commercial performance of CABOMETYX and COMETRIQ. By optimizing the balance sheet, Christopher Senner directly impacts the ability of the firm to scale clinical development programs. Furthermore, Senner manages the long-term financial planning required to support the expansion of oncology portfolios. Through rigorous oversight of budgetary controls, the Executive Vice President & Chief Financial Officer secures the necessary resources to sustain competitive advantages in the pharmaceutical sector while driving sustainable growth for shareholders and stakeholders alike.

Craig Palmer - Senior Vice President, Chief of Staff
Craig Palmer, the Senior Vice President, Chief of Staff at Exelixis, coordinates cross-functional initiatives to streamline internal operations. Overseeing the alignment of executive priorities, the Senior Vice President, Chief of Staff ensures that organizational goals remain synchronized with the broader mission of delivering oncology solutions. This leadership role involves facilitating communication between departments to accelerate the development of new medicines for difficult-to-treat cancers. By managing complex projects, Craig Palmer directly impacts the efficiency of the corporate structure. Furthermore, Palmer monitors the execution of strategic objectives across the enterprise to ensure operational excellence. Through the integration of diverse business functions, the Senior Vice President, Chief of Staff supports the rapid transition of research findings into commercialized products. This role remains essential for maintaining the agility required to navigate the competitive landscape of the pharmaceutical industry while fostering a culture of high performance.
Carol O'Hear - Chief Medical Officer & Head of Clinical Development
Carol O'Hear, the Chief Medical Officer & Head of Clinical Development at Exelixis, directs the scientific strategy for all oncology drug trials. Overseeing the clinical development pipeline, the Chief Medical Officer & Head of Clinical Development ensures that research into inhibitors like MET, AXL, and VEGF receptors meets rigorous safety and efficacy standards. This leadership role involves managing interactions with regulatory bodies to expedite the approval of new therapies for renal cell carcinoma and other malignancies. By guiding the design of complex clinical studies, Carol O'Hear directly impacts the success rate of the drug portfolio. Furthermore, O'Hear supervises the medical affairs team to ensure accurate dissemination of clinical data to healthcare providers. Through the application of deep medical expertise, the Chief Medical Officer & Head of Clinical Development drives the advancement of innovative treatments from the laboratory to the patient, ultimately improving survival rates for individuals facing advanced cancer diagnoses.
Brenda Hefti - General Counsel & Chief Legal Officer
Brenda Hefti, the General Counsel & Chief Legal Officer at Exelixis, manages all legal affairs and intellectual property protections. Overseeing the defense of proprietary technologies, the General Counsel & Chief Legal Officer ensures that the company maintains exclusive rights to its cabozantinib-based inhibitors and other pharmaceutical assets. This leadership role involves navigating complex regulatory environments and mitigating risks associated with global commercialization efforts. By providing strategic legal counsel, Brenda Hefti directly impacts the stability of the corporate business model. Furthermore, Hefti supervises compliance programs to ensure adherence to international healthcare laws and ethical standards. Through the management of litigation and contract negotiations, the General Counsel & Chief Legal Officer protects the interests of the firm during expansion into new therapeutic areas. This role remains critical for safeguarding the long-term value of the research pipeline while ensuring that all business activities align with legal requirements and corporate governance policies.
Explore Leadership Teams in Manufacturing
PiSA Farmacéutica is a socially responsible pharmaceutical company based in Mexico, specializing in the production of over 1,500 brands of medications across 17 specialty lines and 14 production plants. With a workforce of around 30,000 employees, the company emphasizes quality, integrity, and transparency in its operations. PiSA also engages in pharmacovigilance and technovigilance to ensure the safety and efficacy of its products. Their intended clients include hospitals and healthcare providers, reflecting their commitment to improving health outcomes.
Company Leadership AT
CR
YP
AJ
Bharat Serums And Vaccines Limited (BSV) is one of India's fastest-growing biopharmaceutical companies, dedicated to developing a wide range of biological, biotech, and pharmaceutical products for over 50 years. The company focuses on critical therapeutic areas such as women's health, critical care, and assisted reproductive technology, aiming to improve health and save lives through innovative treatments. BSV is committed to enhancing the quality of life for patients globally, with a strong emphasis on research and development, supported by a team of over 60 scientists. As a part of the Mankind Group, BSV strives to widen accessibility to its products and deliver positive health outcomes.
Company LeadershipDaiichi Sankyo is a global healthcare company dedicated to transforming lives through scientific innovation and technology, with a strong focus on oncology. The company develops and commercializes a leading portfolio of antibody drug conjugates (ADCs) and other innovative therapies to address diverse medical needs. Its primary clients include healthcare professionals and patients, as it aims to deliver practice-changing medicines that enhance quality of life. With a commitment to research and development, Daiichi Sankyo strives to advance new standards of care in the healthcare industry.
Company Leadership DM
SK
EM
AY
Founded in 1995, The Ritedose Corporation is a manufacturing and packaging facility, located in Columbia, SC.
Company Leadership
JT
DM
